Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors

Trial Profile

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary) ; Antineoplastics
  • Indications Skin cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Beyond Air

Most Recent Events

  • 10 Feb 2025 According to a Beyond Cancer media release, topline data from the Phase 1b portion of the study are anticipated late in calendar 2025 or early-2026.
  • 03 Dec 2024 According to a Beyond Cancer media release, the company announced that topline data from the Phase 1b portion of the study are anticipated in the second half of 2025.
  • 03 Dec 2024 Planned number of patients changed from 38 to 58.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top